Indonesia is actively seeking to enhance its domestic pharmaceutical manufacturing capabilities through technology transfers with Russia, aiming to reduce its dependency on imported medicines. This initiative is part of a broader strategy to bolster local production and improve regulatory oversight of medical and food products.
The recent discussions, held between Indonesia’s Food and Drug Authority (BPOM) and Russian Deputy Minister of Industry and Trade Alexey Vladimirovich Gruzdev, focused on various aspects of pharmaceutical technology. Key areas of interest include the manufacturing and quality inspection of medicines, as well as the adoption of digital technologies to ensure product safety and traceability.
Indonesia underscored the significance of producing critical healthcare products locally, such as diabetes treatments, including insulin and glucagon-like peptide-1 (GLP-1) medicines. The potential collaboration extends to other therapeutic areas such as cancer treatments, monoclonal antibodies, antiviral medicines, and advanced biotechnology products.
Russian companies have shown interest in transferring technology and potentially setting up manufacturing facilities in Indonesia. This interest is particularly strong in the areas of insulin production, oncology medicines, and biotechnology products. Additionally, several Russian pharmaceutical companies have already submitted product registration documents to BPOM, indicating a concrete step towards collaboration.
The discussions also covered the mutual recognition of Good Manufacturing Practice (GMP) certificates, which could simplify regulatory procedures and facilitate market access for pharmaceutical products in both countries. However, further talks are needed to ensure the compatibility of the regulatory systems between the two nations.
To aid in strengthening Indonesia’s pharmaceutical inspection capabilities, Russia has offered technical training opportunities, including innovative virtual reality-based simulations to prepare inspectors for manufacturing assessments. Both parties are keen to continue negotiations and expand their cooperation through additional meetings and site visits to pharmaceutical manufacturing facilities.